An Innovative Canadian Pharmaceutical Company

Revenue Projected at $160,000,000 by 2025

Sponsored
Message: AGORACOM Small Cap 60: Does Public Reimbursement for Valeo’s Asthma Drugs In Alberta Open The Door to Other Provinces?

AGORACOM Small Cap 60: Does Public Reimbursement for Valeo’s Asthma Drugs In Alberta Open The Door to Other Provinces?

posted on Nov 18, 2021 01:45PM

Share
New Message
Please login to post a reply